EMD Serono
emdserono.comTotal trials
177
Active
19
Phase 3
45
Total enrollment
42,177
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Avelumab | — | — | — | 15 | |||
| Bevacizumab | — | — | — | — | 4 | ||
| Enpatoran | — | — | — | — | — | 2 | |
| Standard of care | — | — | — | — | — | 2 | |
| Precemtabart tocentecan | — | — | — | — | — | 1 | |
| Trifluridine/Tipiracil | — | — | — | — | — | 1 | |
| Tuvusertib | — | — | — | — | 4 | ||
| Tepotinib | — | — | — | — | 4 | ||
| Niraparib | — | — | — | — | 3 | ||
| M1774 | — | — | — | — | 2 | ||
| M9140 | — | — | — | — | 2 | ||
| Lartesertib | — | — | — | — | 2 | ||
| M6223 | — | — | — | — | 2 | ||
| Cemiplimab | — | — | — | — | — | 1 | |
| Osimertinib | — | — | — | — | — | 1 | |
| Sacituzumab Govitecan | — | — | — | — | — | 1 | |
| NKTR-255 | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | 3 | |||
| Pembrolizumab | — | — | — | — | 2 | ||
| 5-fluorouracil | — | — | — | — | 2 | ||
| M9466 | — | — | — | — | — | 3 | |
| Folinic acid | — | — | — | — | — | 2 | |
| M7437 | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| M3554 | — | — | — | — | — | 1 | |
| Abiraterone acetate | — | — | — | — | — | 1 | |
| Prednisone/Prednisolone | — | — | — | — | — | 1 | |
| M0324 | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 |
Next readouts
- 2022-05-16
- 2023-05-11
- 2025-06-20
- 2025-09-29
- 2026-02-11
- 2026-07-30
- 2026-08-21
- 2026-09-30
- 2026-10-23
- 2027-01-14
Top conditions
- Multiple Sclerosis18
- Advanced Solid Tumor10
- Solid Tumors8
- Advanced Solid Tumors6
- Ovarian Cancer6
- Lupus Erythematosus, Systemic4
- Non-small Cell Lung Cancer4
- Carcinoma, Non-Small-Cell Lung4
Frequently asked questions about EMD Serono
- How many clinical trials does EMD Serono have on ClinicalTrials.gov?
- EMD Serono is listed as the lead sponsor on 177 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of EMD Serono's trials are in Phase 3?
- 45 of EMD Serono's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does EMD Serono focus on?
- EMD Serono's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Advanced Solid Tumor, Solid Tumors, Advanced Solid Tumors, Ovarian Cancer.
- When are EMD Serono's next clinical trial readouts?
- EMD Serono has 10 upcoming primary-completion readouts tracked here; the soonest is “Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)”, expected around 2022-05-16.